Third quarter 2022 results
Third quarter 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Featuring
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/PHudson_20230417070709.jpg?size=small)
Paul Hudson
Chief Executive Officer
![Jean-Baptiste de Chatillon](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/JBdeChatillon_20230417070431.png?size=small)
Jean-Baptiste de Chatillon
Chief Financial Officer
![Bill Sibold](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/BillSibold_20230417070309.png?size=small)
Bill Sibold
Specialty Care
![Olivier Charmeil](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/OlivierCharmeil_20230417070553.png?size=small)
Olivier Charmeil
General Medicines
![John Reed](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/J-Reed_20230417070457.jpg?size=small)
John Reed
R&D
![Thomas Triomphe](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/ThomasTriomphe_20230417070802.png?size=small)
Thomas Triomphe
Vaccines
![Julie Van Ongevalle](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/JVOngevalle_20230417070525.png?size=small)
Julie Van Ongevalle
Consumer Healthcare
![Roy Papatheodorou](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/Papathedorou-circle_20230417070637.png?size=small)
Roy Papatheodorou
General Counsel
Highlights
“Our exceptional results for the third quarter demonstrate that Sanofi is on the right path. We delivered remarkable sales growth and our commitment to breakthrough science is bearing fruit as we achieved key regulatory milestones for three of our priority medicines.”
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/ph.jpeg?size=small)
Paul Hudson
Chief Executive Officer, Sanofi